Phase 2 study of CMB305 in patients with tumours
Phase of Trial: Phase II
Latest Information Update: 31 Mar 2015
At a glance
- Drugs CMB 305 (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Sponsors Immune Design
- 31 Mar 2015 According to a company media release, Immune Design plans to commence this expansion study at the optimal dose in patients with any of four tumor types: sarcoma, lung, ovarian and melanoma.
- 17 Dec 2014 New trial record
- 13 Nov 2014 According to an Immune Design media release, this is one of the two phase 2 studies and it is intended to begin in the later part of 2015.